Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
8
Bullish
4
Bearish
17
Neutral
8
Bullish
21
Bearish
15
Neutral
0
Bullish
17
Bearish
2
Neutral
8
Bullish
4
Bearish
2
Neutral
8
Bullish
4
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Abbott India Ltd is a leading multinational pharmaceutical company with a manufacturing facility in Goa and various third-party manufacturers across India.
It operates in therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health, offering a diverse product portfolio.
The company has historic roots dating back to 1944, with multiple name changes reflecting its evolving business focus and strategic mergers.
Abbott India has launched numerous products across therapy segments, indicating significant portfolio expansion and innovation, particularly in gastrointestinal and women's health.
The company leverages strategic partnerships and advanced medical research to drive growth and maintain its strong market position in India.
Pharmaceuticals & Biotechnology
Pharmaceuticals
57,018 Cr
Low Risk
35.3
37.0
3.2
11.9
30,598.00
25,140.50
Sales CAGR
Profit CAGR
ROE
ROCE
Abbott India Ltd (ABBOTINDIA) is currently trading at 26,780.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Abbott India Ltd is a leading multinational pharmaceutical company with a manufacturing facility in Goa and various third-party manufacturers across India. It operates in therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health, offering a diverse product portfolio. The company has historic roots dating back to 1944, with multiple name changes reflecting its evolving business focus and strategic mergers. Abbott India has launched numerous products across therapy segments, indicating significant portfolio expansion and innovation, particularly in gastrointestinal and women's health. The company leverages strategic partnerships and advanced medical research to drive growth and maintain its strong market position in India.
Over the past 52 weeks, Abbott India Ltd has traded between a low of ₹25,140.50 and a high of ₹30,598.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Abbott India Ltd has a market capitalization of approximately 57,018.21. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Abbott India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.31 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 57,018.21 Cr, Abbott India Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Abbott India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Abbott India Ltd is 35.31. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
For the quarter ended June 30, 2026, revenue from operations was ₹1,813.68 crore and profit after tax (PAT) was ₹428.52 crore (standalone).
Abbott India has announced a total dividend of ₹656 per share for the year ended March 31, 2026, comprising a ₹525 final dividend and a ₹131 special dividend.
Abbott India reported consolidated net profit of ₹429 crore in Q1 FY27, up 17.12% from ₹366 crore in Q1 FY26.
The note attributes the downgrade mainly to a shift in technical indicators to bearish territory, along with flat Q3 FY25-26 performance and an expensive valuation profile.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2336.30 | 65,936 Cr | 36.68 | 6.27 | 0.21 | 28.08 | 32.70 | 9.03 | ||
5240.00 | 62,652 Cr | 28.40 | 4.53 | 1.01 | 16.66 | 18.61 | 10.57 | ||
370.90 | 60,445 Cr | 145.16 | 1.75 | 0.13 | 1.14 | 3.64 | 0.65 | ||
26832.10 | 57,018 Cr | 35.31 | 11.94 | 2.44 | 32.51 | 42.54 | 24.83 | ||
1940.35 | 49,228 Cr | 35.68 | 6.10 | 0.31 | 14.15 | 18.58 | 11.15 | ||
2873.60 | 47,418 Cr | 42.01 | 4.58 | 0.70 | 9.92 | 14.02 | 9.02 | ||
2774.50 | 47,002 Cr | 44.00 | 20.73 | 2.05 | 45.69 | 61.23 | 24.70 | ||
| Median: 7 Co. | — | 2774.50 | 57,018 Cr | 36.68 | 6.10 | 0.70 | 16.66 | 18.61 | 10.57 |
